{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:28:36Z","timestamp":1794407316288,"version":"4.9.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The win ratio method for analysing a composite clinical hierarchy of outcomes is growing in popularity especially in cardiovascular trials. This article gives a perspective on its use so far and the issues derived from that experience. Specifically, it focuses on the limitations of a conventional composite outcome; how does the win ratio work, what does it mean, and how to display its findings; guidance on choosing an appropriate clinical hierarchy of outcomes including clinical events, quantitative outcomes, and other options; the additional value of the win difference as a measure of absolute benefit: extension to stratified win ratio, subgroup analysis, matched win ratio, and covariate adjustment; determining trial size for a win ratio outcome; specific insights such as adaptive designs, use of repeat events, and use of margins and time averages for quantitative outcomes; a critique of potential misuses; availability of statistical software; and a statistical appendix on the methodological details. Throughout, each principle is illustrated by examples from specific cardiology trials. The article concludes with a set of recommendations for future use of the win ratio.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehae647","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:52:44Z","timestamp":1726476764000},"page":"4684-4699","source":"Crossref","is-referenced-by-count":121,"title":["The win ratio in cardiology trials: lessons learnt, new developments, and wise future use"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-4007","authenticated-orcid":false,"given":"Stuart J","family":"Pocock","sequence":"first","affiliation":[{"name":"Medical Statistics Department, London School of Hygiene and Tropical Medicine , London, WC1E 7HT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6084-166X","authenticated-orcid":false,"given":"John","family":"Gregson","sequence":"additional","affiliation":[{"name":"Medical Statistics Department, London School of Hygiene and Tropical Medicine , London, WC1E 7HT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-277X","authenticated-orcid":false,"given":"Timothy J","family":"Collier","sequence":"additional","affiliation":[{"name":"Medical Statistics Department, London School of Hygiene and Tropical Medicine , London, WC1E 7HT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Joao Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]},{"name":"F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier R\u00e9gional Universitaire de Nancy , Nancy ,","place":["France"]},{"name":"UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto , Porto ,","place":["Portugal"]},{"name":"Heart Failure Clinic, Internal Medicine Department, Unidade Local de Sa\u00fade de Gaia , Espinho ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-8210","authenticated-orcid":false,"given":"Gregg W","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"2024112100181827300_ehae647-B1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"2024112100181827300_ehae647-B2","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jacc.2023.07.024","article-title":"Recurrent events in cardiovascular trials: JACC state-of-the-art review","volume":"82","author":"Gregson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024112100181827300_ehae647-B3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jchf.2020.02.010","article-title":"Use of the win ratio in cardiovascular trials","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2024112100181827300_ehae647-B4","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: practical guidance based on previous experience","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"2024112100181827300_ehae647-B5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ki.2008.294","article-title":"The analysis of survival data in nephrology: basic concepts and methods of Cox regression","volume":"74","author":"van Dijk","year":"2008","journal-title":"Kidney Int"},{"key":"2024112100181827300_ehae647-B6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.5811\/westjem.2018.4.38383","article-title":"Understanding the use of composite endpoints in clinical trials","volume":"19","author":"McCoy","year":"2018","journal-title":"West J Emerg Med"},{"key":"2024112100181827300_ehae647-B9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/sim.7531","article-title":"A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance","volume":"37","author":"Rauch","year":"2018","journal-title":"Stat Med"},{"key":"2024112100181827300_ehae647-B10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11&lt;1341::AID-SIM129&gt;3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat Med"},{"key":"2024112100181827300_ehae647-B11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B12","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B13","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/sim.3923","article-title":"Generalized pairwise comparisons of prioritized outcomes in the two-sample problem","volume":"29","author":"Buyse","year":"2010","journal-title":"Stat Med"},{"key":"2024112100181827300_ehae647-B14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jacbts.2023.05.004","article-title":"Fallacies of using the win ratio in cardiovascular trials: challenges and solutions","volume":"8","author":"Ajufo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2024112100181827300_ehae647-B15","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/CIRCULATIONAHA.123.067786","article-title":"Win ratio: a seductive but potentially misleading method for evaluating evidence from clinical trials","volume":"149","author":"Butler","year":"2024","journal-title":"Circulation"},{"key":"2024112100181827300_ehae647-B16","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2015.10.014","article-title":"Making sense of statistics in clinical trial reports: part 1 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024112100181827300_ehae647-B17","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1002\/sim.8967","article-title":"Win odds: an adaptation of the win ratio to include ties","volume":"40","author":"Brunner","year":"2021","journal-title":"Stat Med"},{"key":"2024112100181827300_ehae647-B18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Eng J Med"},{"key":"2024112100181827300_ehae647-B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"2024112100181827300_ehae647-B23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B24","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.jacc.2019.03.484","article-title":"Statistical appraisal of 6 recent clinical trials in cardiology: JACC state-of-the-art review","volume":"73","author":"Pocock","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024112100181827300_ehae647-B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.070870","article-title":"Interatrial shunt treatment for heart failure: The randomized RELIEVE-HF trial","author":"Stone","journal-title":"Circulation"},{"key":"2024112100181827300_ehae647-B26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejhf.2853","article-title":"The win ratio method in heart failure trials: lessons learnt from EMPULSE","volume":"25","author":"Pocock","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2024112100181827300_ehae647-B27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2024112100181827300_ehae647-B28","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"key":"2024112100181827300_ehae647-B31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/00001648-199209000-00009","article-title":"Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint","volume":"3","author":"Ragland","year":"1992","journal-title":"Epidemiology"},{"key":"2024112100181827300_ehae647-B32"},{"key":"2024112100181827300_ehae647-B33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/pst.1743","article-title":"A win ratio approach to comparing continuous non-normal outcomes in clinical trials","volume":"15","author":"Wang","year":"2016","journal-title":"Pharm Stat"},{"key":"2024112100181827300_ehae647-B34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa052980","article-title":"NXY-059 for acute ischemic stroke","volume":"354","author":"Lees","year":"2006","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B35"},{"key":"2024112100181827300_ehae647-B36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0140-6736(19)32972-1","article-title":"Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial","volume":"395","author":"Holm","year":"2020","journal-title":"Lancet"},{"key":"2024112100181827300_ehae647-B37","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1056\/NEJMoa1909406","article-title":"Five-year outcomes after PCI or CABG for left main coronary disease","volume":"381","author":"Stone","year":"2019","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B38","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2024112100181827300_ehae647-B39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/dom.12263","article-title":"Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin","volume":"16","author":"Grandy","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2024112100181827300_ehae647-B40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2337\/dc20-1675","article-title":"Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF","volume":"44","author":"Inzucchi","year":"2021","journal-title":"Diabetes Care"},{"key":"2024112100181827300_ehae647-B41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMra1510064","article-title":"The primary outcome fails\u2014what next?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"key":"2024112100181827300_ehae647-B42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","article-title":"Safety and efficacy of renal denervation in patients taking antihypertensive medications","volume":"82","author":"Kandzari","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024112100181827300_ehae647-B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2024.07.002","article-title":"Results of the COMPASS trial analyzed using win ratio compared with conventional analytic approaches","volume":"In Press","author":"Eikelboom","year":"2024","journal-title":"Canadian Journal of Cardiology"},{"key":"2024112100181827300_ehae647-B44","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/sim.4102","article-title":"Adaptive increase in sample size when interim results are promising: a practical guide with examples","volume":"30","author":"Mehta","year":"2011","journal-title":"Stat Med"},{"key":"2024112100181827300_ehae647-B45","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/bcp.13280","article-title":"Defining the noninferiority margin and analysing noninferiority: an overview","volume":"83","author":"Althunian","year":"2017","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/44\/4684\/60751032\/ehae647.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/44\/4684\/60751032\/ehae647.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T19:18:33Z","timestamp":1732130313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/44\/4684\/7822474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":45,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2024,10,15]]},"published-print":{"date-parts":[[2024,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae647","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,21]]},"published":{"date-parts":[[2024,10,15]]}}}